查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2064879

低溫低溫運輸包裝市場預測至2034年—按產品類型、溫度範圍、絕緣類型、監控類型、應用、最終用戶和地區分類的全球分析

Cryogenic Cold Chain Packaging Market Forecasts to 2034 - Global Analysis By Product Type, Temperature Range, Insulation Type, Monitoring Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球低溫低溫運輸包裝市場規模將達到 31 億美元，並在預測期內以 13.6% 的複合年成長率成長，到 2034 年將達到 86 億美元。

低溫低溫運輸包裝是指專門設計的儲存和運輸系統，旨在將生物、製藥和臨床材料在整個儲存和運輸過程中維持在極低的溫度，範圍從-40°C到低於-150°C。這些系統包括低溫管瓶、杜瓦瓶、液態氮運輸容器、保溫容器、冷凍箱和低溫袋，它們採用真空絕熱板、聚氨酯泡棉、發泡聚苯乙烯、氣凝膠和多層隔熱技術，並應用於細胞治療、疫苗運輸、生物樣本庫和生殖醫學等領域。

拓展細胞和基因治療產品線

細胞和基因療法臨床計畫及商業化產品上市的爆炸性成長是推動低溫低溫運輸包裝需求的主要因素。自體和異體細胞療法，包括CAR-T細胞產品，從生產到患者用藥都需要在-150°C以下的溫度下儲存，這導致了複雜的多地點低溫運輸要求。每個患者的治療週期都需要專門的低溫包裝，用於細胞的收集、處理、儲存和輸送。已獲批准的細胞和基因療法產品線的快速成長以及全球臨床試驗數量的增加，持續推動對具備完整監管文件的、經過檢驗的低溫包裝解決方案的需求。

液態氮供應鏈的複雜性

使用液態氮作為冷卻介質的低溫包裝系統需要專門的處理基礎設施、訓練有素的人員、安全規程以及可靠的液態氮供應物流，這顯著增加了臨床和商業分銷環境中的營運複雜性。許多位於主要都會區以外的醫院、診所和研究機構缺乏安全接收和處理液態氮運輸的基礎設施。低溫材料運輸的相關規定增加了文件記錄和合規性的負擔。這些基礎設施的限制使得細胞療法和先進生技藥品的低溫低溫運輸分銷網路在全球範圍內的覆蓋範圍受到限制。

擴大mRNA疫苗的低溫運輸

mRNA疫苗技術平台已證實具有臨床療效，且其研發管線正迅速擴展，涵蓋從新冠肺炎到流感、腫瘤和感染疾病領域，這導致對低溫包裝解決方案的需求持續旺盛。 mRNA療法需要在-70°C至-80°C的溫度下進行持續儲存和運輸，因此，經過檢驗的低溫運輸容器和溫度監測解決方案在整個分銷網路中至關重要。隨著新一代mRNA疫苗生產商推進其研發線產品的商業化進程，他們正在投資建造專用的低溫分銷基礎設施，預計這將顯著增加預測期內低溫包裝的採購量。

乾冰供應和價格波動

乾冰供應和價格的顯著波動給依賴乾冰作為超低溫（CFC）包裝運輸冷卻介質的製藥和生物技術低溫運輸營運商帶來營運風險。例如，在新冠疫苗部署期間，由於二氧化碳生產短缺導致乾冰供應中斷，可能會嚴重影響對時間要求嚴格的生技藥品低溫運輸的連續性。乾冰成本上漲降低了傳統低溫包裝的經濟吸引力，可能迫使營運商使用高成本的替代冷媒。這些供應鏈脆弱性正在強化全球低溫低溫運輸專案業務風險規劃的重要性。

新冠疫情的影響

新冠疫情已成為低溫低溫運輸包裝技術的變革性催化劑，促使人們對低溫儲存和運輸基礎設施進行前所未有的投資，以支持mRNA疫苗的全球分發。疫情暴露了全球醫療系統低溫包裝能力的嚴重短缺，加速了數十億美元對低溫運輸基礎設施的投資。疫情過後，為新冠疫苗建立的擴展低溫運輸能力和檢驗的運輸網路基礎設施，如今已成為細胞療法、mRNA療法和先進生技藥品快速擴展分發計劃的商業性基礎。

在預測期內，保溫容器細分市場預計將佔據最大的市場佔有率。

由於其在製藥、臨床和研究領域的低溫運輸應用中具有廣泛的適用性，預計在預測期內，保溫容器細分市場將佔據最大的市場佔有率。在這些領域，需要在數天的運輸過程中保持可靠的溫度。採用真空絕熱板和先進氣凝膠隔熱材料的高性能保溫容器能夠提供被動式低溫包裝無法實現的、經過檢驗的低溫保持時間。領先的藥品批發商和臨床研究機構正在推廣使用經認證的保溫容器平台，用於在全球範圍內運輸臨床實驗室用品和商業生技藥品，這些運輸過程需要全面的溫度資料登錄和監管文件。

在預測期內，超低溫（-80 度C至 -40 度C）細分市場預計將呈現最高的複合年成長率。

在預測期內，-80 度C至 -40 度C 的超低溫市場檢驗將呈現最高的成長率，這主要得益於 mRNA 疫苗、細胞治療產品和先進生物製藥的商業分銷需求快速成長，而這些產品都需要經過驗證的超低溫運輸條件。此溫度範圍涵蓋了目前大多數已通過核准和處於後期研發階段的細胞和基因治療產品以及 mRNA 候選疫苗的儲存要求。此溫度範圍內臨床試驗數量的增加和市場新品上市的擴大，正推動全球對檢驗的超低溫運輸平台和監測解決方案的持續投資。

市佔率最大的地區

在預測期內，北美地區預計將佔據最大的市場佔有率，這主要得益於該地區高度集中的細胞治療生產設施、完善的藥品低溫運輸物流基礎設施以及對低溫包裝解決方案需求旺盛的臨床研究運作。美國擁有全球大部分已獲得商業已通過核准的細胞和基因治療產品，並具備全球最大的mRNA疫苗生產能力。領先的低溫包裝製造商，例如賽默飛世爾科技（Thermo Fisher Scientific）、CSafe Global, LLC和Pelican BioThermal LLC，均在該地區設有主要基地，從而確保供應鏈接近性最大的需求中心。

複合年成長率最高的地區

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於中國、韓國、日本、新加坡和印度等國製藥生產投資的快速成長，細胞和基因療法臨床試驗項目的增加，以及政府主導的生物製藥產業的發展。該地區生物相似藥和mRNA疫苗產能的擴張，也推動了對檢驗的低溫包裝基礎設施的需求成長。新興亞洲經濟體醫療系統對先進療法和低溫運輸能力的投資，將在整個預測期帶來強勁的新市場成長。

免費客製化服務

所有購買此報告的客戶均可享受以下免費自訂選項之一。

  • 企業概況
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 透過產品系列、地理覆蓋範圍和策略聯盟對標領先企業。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 成長機會和重點投資領域
  • 工業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球低溫低溫運輸包裝市場：依產品類型分類

  • 低溫管瓶和導管
  • 杜瓦和坦克
  • 低溫運輸容器
  • 低溫冷凍庫和冷藏箱
  • 保溫容器
  • 低溫袋

第6章 全球低溫低溫運輸包裝市場：依溫度範圍分類

  • 超低溫（-80 度C至 -40 度C）
  • 深低溫（-150 度C至 -80 度C）
  • 低溫（低於-150 度C）

第7章 全球低溫低溫運輸包裝市場：依絕緣類型分類

  • 真空絕熱板
  • 聚氨酯泡棉
  • 發泡聚苯乙烯
  • 氣凝膠絕緣隔熱材料
  • 多層隔熱材料

第8章 全球低溫低溫運輸包裝市場：依監測類型分類

  • 主動溫度監測系統
  • 被動式溫度監測
  • RFID和物聯網包裝
  • 數據記錄器

第9章 全球低溫低溫運輸包裝市場：依應用領域分類

  • 細胞和基因治療
  • 疫苗儲存和運輸
  • 生物樣本的保存
  • 醫藥原料
  • 臨床試驗用材料
  • 生殖醫學
  • 血液和血漿製品

第10章 全球低溫低溫運輸包裝市場：依最終用戶分類

  • 製藥和生物技術公司
  • 臨床研究機構
  • 醫院和診斷中心
  • 血庫
  • 學術研究機構

第11章 全球低溫低溫運輸包裝市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 其他
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲地區

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章：產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟、合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Thermo Fisher Scientific Inc.
  • Chart Industries, Inc.
  • Cryopak Industries Inc.
  • Sonoco Products Company
  • Softbox Systems Ltd.
  • CSafe Global, LLC
  • Pelican BioThermal LLC
  • Intelsius Ltd.
  • Air Liquide SA
  • Linde plc
  • Worthington Industries, Inc.
  • Taylor-Wharton International LLC
  • Praxisdienst GmbH
  • Eppendorf AG
  • Brooks Automation, Inc.
  • Haier Biomedical
  • PHC Holdings Corporation
  • Binder GmbH
Product Code: SMRC36855

According to Stratistics MRC, the Global Cryogenic Cold Chain Packaging Market is accounted for $3.1 billion in 2026 and is expected to reach $8.6 billion by 2034 growing at a CAGR of 13.6% during the forecast period. Cryogenic cold chain packaging refers to specialized containment and transport systems engineered to maintain biological, pharmaceutical, and clinical materials at ultra-low and cryogenic temperatures ranging from minus 40 degrees Celsius to below minus 150 degrees Celsius throughout storage and distribution operations. These systems encompass cryogenic vials, dewars, liquid nitrogen shippers, insulated containers, freezer boxes, and cryogenic bags utilizing vacuum insulation panels, polyurethane foam, expanded polystyrene, aerogel, and multi-layer insulation technologies, serving cell therapy, vaccine transport, biological sample banking, and reproductive medicine applications.

Market Dynamics:

Driver:

Cell and gene therapy pipeline growth

The explosive growth of cell and gene therapy clinical programs and commercial product launches is the foremost driver of cryogenic cold chain packaging demand. Autologous and allogeneic cell therapies, including CAR-T cell products, require maintained cryogenic storage at minus 150 degrees Celsius or below from manufacturing through patient administration, creating complex multi-node cold chain requirements. Each patient treatment cycle demands dedicated cryogenic packaging for cell collection, processing, storage, and delivery. The rapidly expanding approved cell and gene therapy product pipeline and global clinical trial volume generate sustained demand for validated cryogenic packaging solutions with full regulatory documentation.

Restraint:

Liquid nitrogen supply chain complexity

Cryogenic packaging systems utilizing liquid nitrogen as the coolant medium require specialized handling infrastructure, trained personnel, safety protocols, and reliable nitrogen supply logistics that create significant operational complexity in clinical and commercial distribution environments. Many hospitals, clinics, and research facilities outside major urban centers lack the infrastructure to safely receive and handle liquid nitrogen cryogenic shipments. Regulatory requirements governing the transport of cryogenic materials add documentation and compliance burden. These infrastructure limitations constrain the geographic reach of cryogenic cold chain distribution networks for cell therapy and advanced biological products globally.

Opportunity:

mRNA vaccine cold chain expansion

The proven clinical efficacy of mRNA vaccine technology platforms and their rapid pipeline expansion beyond COVID-19 into influenza, oncology, and infectious disease applications creates substantial ongoing demand for ultra-low temperature cryogenic packaging solutions. mRNA therapeutics require consistent storage and transport at minus 70 to minus 80 degrees Celsius, necessitating validated cryogenic shippers and temperature monitoring solutions throughout the distribution network. Manufacturers of next-generation mRNA vaccines are investing in dedicated ultra-cold distribution infrastructure as pipeline products progress toward commercial launch, creating significant cryogenic packaging procurement volume growth through the forecast period.

Threat:

Dry ice supply and cost volatility

Significant volatility in dry ice supply availability and pricing creates operational risk for pharmaceutical and biotech cold chain operators dependent on dry ice as the coolant medium for ultra-low temperature cryogenic packaging shipments. Dry ice supply disruptions caused by carbon dioxide production shortfalls, as experienced during COVID-19 vaccine rollout operations, can critically compromise cold chain continuity for time-sensitive biological materials. Rising dry ice costs reduce the economic attractiveness of conventional cryogenic packaging formats and may force operators toward higher-cost refrigerant alternatives. These supply chain vulnerabilities increase operational risk planning requirements for cryogenic cold chain programs globally.

Covid-19 Impact:

COVID-19 was a transformative catalyst for cryogenic cold chain packaging, driving unprecedented investment in ultra-low temperature storage and transport infrastructure to support global mRNA vaccine distribution. The pandemic exposed critical cryogenic packaging capacity gaps in healthcare systems worldwide and accelerated multi-billion-dollar investments in cold chain infrastructure. Post-pandemic, the expanded cryogenic cold chain capacity and validated shipping network infrastructure established for COVID vaccines now serve as the commercial foundation for rapidly scaling cell therapy, mRNA therapeutic, and advanced biologic distribution programs.

The insulated containers segment is expected to be the largest during the forecast period

The insulated containers segment is expected to account for the largest market share during the forecast period, due to their broad applicability across pharmaceutical, clinical, and research cold chain applications requiring reliable temperature maintenance over multi-day transport durations. High-performance insulated containers utilizing vacuum insulated panels and advanced aerogel insulation deliver validated ultra-low temperature hold times that passive cryogenic packaging cannot achieve. Leading pharmaceutical distributors and clinical research organizations standardize on certified insulated container platforms for global clinical trial material and commercial biologic shipments requiring comprehensive temperature data logging and regulatory documentation.

The ultra-low temperature -80°C to -40°C segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the ultra-low temperature -80°C to -40°C segment is predicted to witness the highest growth rate, driven by rapidly expanding commercial distribution requirements for mRNA vaccines, cell therapy products, and advanced biologics requiring validated ultra-cold transport conditions. This temperature range encompasses the storage requirements of the majority of currently approved and late-stage pipeline cell and gene therapy products and mRNA vaccine candidates. Growing clinical trial volumes and commercial product launches within this temperature segment drive consistent capital investment in validated ultra-low temperature shipping platforms and monitoring solutions globally.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the highest concentration of cell therapy manufacturing facilities, pharmaceutical cold chain logistics infrastructure, and clinical research operations requiring cryogenic packaging solutions. The United States hosts the majority of commercially approved cell and gene therapy products and the largest mRNA vaccine manufacturing capacity globally. Leading cryogenic packaging manufacturers, including Thermo Fisher Scientific Inc., CSafe Global, LLC, and Pelican BioThermal LLC, maintain their primary operations in the region, ensuring supply chain proximity to the largest demand centers.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding pharmaceutical manufacturing investment, growing cell and gene therapy clinical trial programs, and government-backed biopharmaceutical industry development across China, South Korea, Japan, Singapore, and India. Regional biosimilar and mRNA vaccine manufacturing capacity expansion creates growing demand for validated cryogenic packaging infrastructure. Healthcare system investment in advanced therapy access and cold chain capability across emerging Asian economies generates strong new market growth throughout the forecast period.

Key players in the market

Some of the key players in Cryogenic Cold Chain Packaging Market include Thermo Fisher Scientific Inc., Chart Industries, Inc., Cryopak Industries Inc., Sonoco Products Company, Softbox Systems Ltd., CSafe Global, LLC, Pelican BioThermal LLC, Intelsius Ltd., Air Liquide S.A., Linde plc, Worthington Industries, Inc., Taylor-Wharton International LLC, Praxisdienst GmbH, Eppendorf AG, Brooks Automation, Inc., Haier Biomedical, PHC Holdings Corporation, and Binder GmbH.

Key Developments:

In May 2026, Thermo Fisher Scientific Inc. launched a new range of IoT-connected ultra-low temperature cryogenic shippers with integrated cloud-based temperature monitoring and GPS tracking, enabling pharmaceutical companies to achieve real-time cold chain visibility for cell therapy distribution.

In April 2026, CSafe Global, LLC introduced the RKN e3 active cryogenic container with extended autonomy for ultra-low temperature air freight, providing validated minus 80 degrees Celsius performance over 144-hour shipping durations without dry ice replenishment requirements.

In March 2026, Pelican BioThermal LLC expanded its Credo ultra-low temperature passive shipper portfolio with a new compact format targeting clinical trial sample return shipments, offering 96-hour validated performance at minus 70 degrees Celsius for investigational biological specimens.

Product Types Covered:

  • Cryogenic Vials and Tubes
  • Dewars and Tanks
  • Cryogenic Shippers
  • Cryogenic Freezers and Boxes
  • Insulated Containers
  • Cryogenic Bags

Temperature Ranges Covered:

  • Ultra-Low Temperature -80°C to -40°C
  • Deep Frozen -150°C to -80°C
  • Cryogenic Below -150°C

Insulation Types Covered:

  • Vacuum Insulated Panels
  • Polyurethane Foam
  • Expanded Polystyrene
  • Aerogel-based Insulation
  • Multi-Layer Insulation

Monitoring Types Covered:

  • Active Temperature Monitoring Systems
  • Passive Temperature Monitoring
  • RFID and IoT Enabled Packaging
  • Data Loggers

Applications Covered:

  • Cell and Gene Therapy
  • Vaccine Storage and Transport
  • Biological Sample Storage
  • Pharmaceutical Ingredients
  • Clinical Trial Materials
  • Reproductive Medicine
  • Blood and Plasma Products

End Users Covered:

  • Pharmaceutical and Biotechnology Companies
  • Clinical Research Organizations
  • Hospitals and Diagnostic Centers
  • Blood Banks
  • Academic and Research Institutes

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Cryogenic Cold Chain Packaging Market, By Product Type

  • 5.1 Cryogenic Vials and Tubes
  • 5.2 Dewars and Tanks
  • 5.3 Cryogenic Shippers
  • 5.4 Cryogenic Freezers and Boxes
  • 5.5 Insulated Containers
  • 5.6 Cryogenic Bags

6 Global Cryogenic Cold Chain Packaging Market, By Temperature Range

  • 6.1 Ultra-Low Temperature -80°C to -40°C
  • 6.2 Deep Frozen -150°C to -80°C
  • 6.3 Cryogenic Below -150°C

7 Global Cryogenic Cold Chain Packaging Market, By Insulation Type

  • 7.1 Vacuum Insulated Panels
  • 7.2 Polyurethane Foam
  • 7.3 Expanded Polystyrene
  • 7.4 Aerogel-based Insulation
  • 7.5 Multi-Layer Insulation

8 Global Cryogenic Cold Chain Packaging Market, By Monitoring Type

  • 8.1 Active Temperature Monitoring Systems
  • 8.2 Passive Temperature Monitoring
  • 8.3 RFID and IoT Enabled Packaging
  • 8.4 Data Loggers

9 Global Cryogenic Cold Chain Packaging Market, By Application

  • 9.1 Cell and Gene Therapy
  • 9.2 Vaccine Storage and Transport
  • 9.3 Biological Sample Storage
  • 9.4 Pharmaceutical Ingredients
  • 9.5 Clinical Trial Materials
  • 9.6 Reproductive Medicine
  • 9.7 Blood and Plasma Products

10 Global Cryogenic Cold Chain Packaging Market, By End User

  • 10.1 Pharmaceutical and Biotechnology Companies
  • 10.2 Clinical Research Organizations
  • 10.3 Hospitals and Diagnostic Centers
  • 10.4 Blood Banks
  • 10.5 Academic and Research Institutes

11 Global Cryogenic Cold Chain Packaging Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Thermo Fisher Scientific Inc.
  • 14.2 Chart Industries, Inc.
  • 14.3 Cryopak Industries Inc.
  • 14.4 Sonoco Products Company
  • 14.5 Softbox Systems Ltd.
  • 14.6 CSafe Global, LLC
  • 14.7 Pelican BioThermal LLC
  • 14.8 Intelsius Ltd.
  • 14.9 Air Liquide S.A.
  • 14.10 Linde plc
  • 14.11 Worthington Industries, Inc.
  • 14.12 Taylor-Wharton International LLC
  • 14.13 Praxisdienst GmbH
  • 14.14 Eppendorf AG
  • 14.15 Brooks Automation, Inc.
  • 14.16 Haier Biomedical
  • 14.17 PHC Holdings Corporation
  • 14.18 Binder GmbH

List of Tables

  • Table 1 Global Cryogenic Cold Chain Packaging Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Cryogenic Cold Chain Packaging Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Cryogenic Cold Chain Packaging Market Outlook, By Cryogenic Vials and Tubes (2023-2034) ($MN)
  • Table 4 Global Cryogenic Cold Chain Packaging Market Outlook, By Dewars and Tanks (2023-2034) ($MN)
  • Table 5 Global Cryogenic Cold Chain Packaging Market Outlook, By Cryogenic Shippers (2023-2034) ($MN)
  • Table 6 Global Cryogenic Cold Chain Packaging Market Outlook, By Cryogenic Freezers and Boxes (2023-2034) ($MN)
  • Table 7 Global Cryogenic Cold Chain Packaging Market Outlook, By Insulated Containers (2023-2034) ($MN)
  • Table 8 Global Cryogenic Cold Chain Packaging Market Outlook, By Cryogenic Bags (2023-2034) ($MN)
  • Table 9 Global Cryogenic Cold Chain Packaging Market Outlook, By Temperature Range (2023-2034) ($MN)
  • Table 10 Global Cryogenic Cold Chain Packaging Market Outlook, By Ultra-Low Temperature -80°C to -40°C (2023-2034) ($MN)
  • Table 11 Global Cryogenic Cold Chain Packaging Market Outlook, By Deep Frozen -150°C to -80°C (2023-2034) ($MN)
  • Table 12 Global Cryogenic Cold Chain Packaging Market Outlook, By Cryogenic Below -150°C (2023-2034) ($MN)
  • Table 13 Global Cryogenic Cold Chain Packaging Market Outlook, By Insulation Type (2023-2034) ($MN)
  • Table 14 Global Cryogenic Cold Chain Packaging Market Outlook, By Vacuum Insulated Panels (2023-2034) ($MN)
  • Table 15 Global Cryogenic Cold Chain Packaging Market Outlook, By Polyurethane Foam (2023-2034) ($MN)
  • Table 16 Global Cryogenic Cold Chain Packaging Market Outlook, By Expanded Polystyrene (2023-2034) ($MN)
  • Table 17 Global Cryogenic Cold Chain Packaging Market Outlook, By Aerogel-based Insulation (2023-2034) ($MN)
  • Table 18 Global Cryogenic Cold Chain Packaging Market Outlook, By Multi-Layer Insulation (2023-2034) ($MN)
  • Table 19 Global Cryogenic Cold Chain Packaging Market Outlook, By Monitoring Type (2023-2034) ($MN)
  • Table 20 Global Cryogenic Cold Chain Packaging Market Outlook, By Active Temperature Monitoring Systems (2023-2034) ($MN)
  • Table 21 Global Cryogenic Cold Chain Packaging Market Outlook, By Passive Temperature Monitoring (2023-2034) ($MN)
  • Table 22 Global Cryogenic Cold Chain Packaging Market Outlook, By RFID and IoT Enabled Packaging (2023-2034) ($MN)
  • Table 23 Global Cryogenic Cold Chain Packaging Market Outlook, By Data Loggers (2023-2034) ($MN)
  • Table 24 Global Cryogenic Cold Chain Packaging Market Outlook, By Application (2023-2034) ($MN)
  • Table 25 Global Cryogenic Cold Chain Packaging Market Outlook, By Cell and Gene Therapy (2023-2034) ($MN)
  • Table 26 Global Cryogenic Cold Chain Packaging Market Outlook, By Vaccine Storage and Transport (2023-2034) ($MN)
  • Table 27 Global Cryogenic Cold Chain Packaging Market Outlook, By Biological Sample Storage (2023-2034) ($MN)
  • Table 28 Global Cryogenic Cold Chain Packaging Market Outlook, By Pharmaceutical Ingredients (2023-2034) ($MN)
  • Table 29 Global Cryogenic Cold Chain Packaging Market Outlook, By Clinical Trial Materials (2023-2034) ($MN)
  • Table 30 Global Cryogenic Cold Chain Packaging Market Outlook, By Reproductive Medicine (2023-2034) ($MN)
  • Table 31 Global Cryogenic Cold Chain Packaging Market Outlook, By Blood and Plasma Products (2023-2034) ($MN)
  • Table 32 Global Cryogenic Cold Chain Packaging Market Outlook, By End User (2023-2034) ($MN)
  • Table 33 Global Cryogenic Cold Chain Packaging Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) ($MN)
  • Table 34 Global Cryogenic Cold Chain Packaging Market Outlook, By Clinical Research Organizations (2023-2034) ($MN)
  • Table 35 Global Cryogenic Cold Chain Packaging Market Outlook, By Hospitals and Diagnostic Centers (2023-2034) ($MN)
  • Table 36 Global Cryogenic Cold Chain Packaging Market Outlook, By Blood Banks (2023-2034) ($MN)
  • Table 37 Global Cryogenic Cold Chain Packaging Market Outlook, By Academic and Research Institutes (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.